Anbio Biotechnology
Anbio Biotechnology is a U.S.-based diagnostics company organized through a foreign private issuer structure with principal executive offices in Frankfurt, Germany. It develops and markets in vitro and in vivo diagnostic substances used in medical testing and related laboratory workflows.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueReagents and substances used to detect or measure analytes in laboratory and point-of-care testing.
Compounds used in diagnostic procedures performed within the body or in clinical settings.
Ancillary reagents, kits, and consumable materials used alongside diagnostic assays.
Components and materials supplied for clinical testing and laboratory workflow support.
Customers
The company serves healthcare and laboratory buyers that need diagnostic substances for testing and analysis. Its customers are typically clinical laboratories, hospitals, diagnostic service providers, and other medical-testing organizations that purchase reagents and assay materials to support routine and specialized testing. Because the business is tied to regulated diagnostics workflows, buyers value product reliability, consistency, and compatibility with established instruments and laboratory processes.
Buy diagnostic reagents and substances for routine and specialized lab tests, where accuracy and reproducibility matter.
Purchase diagnostic materials for in-house laboratory operations and patient testing workflows.
Use assay materials and test substances to deliver outsourced or reference testing services.
Acquire diagnostic substances for validation, screening, and laboratory applications.
Strategy
The company’s strategic position is tied to building a diagnostics platform around in vitro and in vivo substances used in clinical testing. Its filings also show an emphasis on maintaining a formal corporate and governance structure, including capital and shareholder actions typical of a growth-stage public issuer. In a diagnostics business, product reliability, regulatory compliance, and customer adoption are central to competitive positioning.
Broader customer adoption increases recurring demand for reagents and assay materials.
Diagnostics businesses depend on validation, consistency, and compliance with health-sector standards.
Public diagnostics companies often need flexibility to fund product development and commercial scale-up.
Geography
2025Anbio Biotechnology is incorporated in the United States but its principal executive office is in Frankfurt, Germany, reflecting a cross-border operating structure. The available filings do not disclose a detailed revenue split by country or region, so the geographic footprint should be viewed as enterprise-wide rather than map-specific. Its location profile suggests exposure to both U.S. and international regulatory and operational requirements.
Share of the revenue the company reports by geography.
Risks
The main business risk is execution in a regulated diagnostics market, where product performance, approvals, and customer adoption determine commercial success. As a cross-border issuer, the company also faces governance, reporting, and operational complexity across jurisdictions. Diagnostics companies additionally face supply-chain, quality-control, and reimbursement pressures that can affect demand and operating continuity.
- Regulatory and compliance riskImpact: HighLikelihood: Medium
Diagnostic substances are used in healthcare settings and must meet technical and regulatory requirements.
Exposure - Product quality and performance riskImpact: HighLikelihood: Medium
Testing materials must deliver consistent results, and failures can damage customer trust and adoption.
Exposure - Cross-border operating complexityImpact: MediumLikelihood: High
The company’s U.S. identity and German executive base indicate multi-jurisdictional administration.
Exposure
Accounting
Judgemental itemsDiagnostic substances and reagents can become obsolete, expire, or require write-downs.
Impact: Can affect cost of sales and balance-sheet carrying values
Quality issues, returns, or product claims may require accruals in a regulated products business.
Impact: Can create period-to-period earnings volatility
The company’s filings discuss multiple ordinary share classes and authorized capital changes.
Impact: Affects dilution, voting control, and equity presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
iBio, Inc.
IBIO · Pharmaceutical Preparations
Abpro Holdings, Inc.
ABPWW · Biological Products, (No Diagnostic Substances)
YD Bio Ltd
YDES · Services-Medical Laboratories
YD Bio Ltd is a U.S.-anchored biotechnology and medical-laboratory services company with operations spanning regulated diagnostics, life science clinical…
Yubo International Biotech Ltd
YBGJ · Electromedical & Electrotherapeutic Apparatus
Yubo International Biotech Ltd is a U.S.-listed holding company whose operating business is conducted in China through Yubo International Biotech (Beijing)…
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
IN8bio, Inc
INAB · Biological Products, (No Diagnostic Substances)
Last updated: 28/09/2026